Arcblock (ABT) shot up by more than 45% in the past 24 hours and claimed a daily high of $1.92, facing resistance at $2.
The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter, Abbott ...
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...
Gov. Abbott sent letters on Thursday to U.S. Congressional leaders requesting the federal government reimburse Texas $11.1 billion for border budget.
The National Investigation Agency (NIA) Special Court, Guwahati (Assam), has sentenced two accused to imprisonment in the ABT ...